- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000636
Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection
To evaluate and compare the effectiveness of a 2-month regimen of rifampin and pyrazinamide versus a 1-year course of isoniazid (INH) to prevent the development of tuberculosis in patients who are coinfected with HIV and latent Mycobacterium tuberculosis (MTb).
Current guidelines recommend 6 to 12 months of treatment with INH for purified protein derivative (PPD)-positive individuals. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to INH-resistant organisms. Studies suggest that two or three months of rifampin and pyrazinamide may be more effective than longer courses of INH. A two-month prevention course should help to increase compliance. In addition, the use of two drugs (rifampin and pyrazinamide) may help overcome problems with drug resistance.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Current guidelines recommend 6 to 12 months of treatment with INH for purified protein derivative (PPD)-positive individuals. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to INH-resistant organisms. Studies suggest that two or three months of rifampin and pyrazinamide may be more effective than longer courses of INH. A two-month prevention course should help to increase compliance. In addition, the use of two drugs (rifampin and pyrazinamide) may help overcome problems with drug resistance.
After baseline screening, patients are randomized to one of two treatment arms and are evaluated by means of clinic visits monthly for the first three months, then every three months for the first year (there are additional clinic visits for INH patients). Patients are then evaluated every six months. One group of patients takes INH plus vitamin B6 for 12 months. The other group of patients takes 1 of 2 doses of rifampin (depending on patient's weight) plus pyrazinamide in 3-4 divided doses for 60 days.
Study Type
Enrollment
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- Community Consortium / UCSF
-
-
Colorado
-
Denver, Colorado, United States, 802044507
- Denver CPCRA / Denver Public Hlth
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Hill Health Corp
-
-
Delaware
-
Wilmington, Delaware, United States, 19899
- Wilmington Hosp / Med Ctr of Delaware
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20422
- Veterans Administration Med Ctr / Regional AIDS Program
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- AIDS Research Consortium of Atlanta
-
-
Illinois
-
Chicago, Illinois, United States, 60657
- AIDS Research Alliance - Chicago
-
Chicago, Illinois, United States, 60605
- Chicago Dept of Health / Speciality STD Clinic
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Louisiana Comm AIDS Rsch Prog / Tulane Univ Med
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins Univ / Brazil
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins Univ / School of Hygiene & Public Health
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston Dept of Health and Hosps
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hosp
-
Detroit, Michigan, United States, 48201
- Comprehensive AIDS Alliance of Detroit
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- Southern New Jersey AIDS Cln Trials / Dept of Med
-
Newark, New Jersey, United States, 07102
- Saint Michael's Med Ctr
-
Newark, New Jersey, United States, 07103
- North Jersey Community Research Initiative
-
Newark, New Jersey, United States, 07103
- Lattimore Comprehensive Pulmonary Disease Clinic
-
-
New York
-
Bronx, New York, United States, 10456
- Bronx Lebanon Hosp Ctr
-
Brooklyn, New York, United States, 11201
- Addiction Research and Treatment Corp
-
New York, New York, United States, 10011
- Clinical Directors Network of Region II
-
New York, New York, United States, 10037
- Harlem AIDS Treatment Group / Harlem Hosp Ctr
-
New York, New York, United States, 10035
- Beth Israel Med Ctr
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Philadelphia FIGHT
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Richmond AIDS Consortium
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Concurrent Medication:
Allowed:
- Antiretroviral treatment.
- Pneumocystis carinii pneumonia prophylaxis.
- Treatment for acute opportunistic infection/malignancy.
- Aminoglycosides, quinolones or fluoroquinolones such as ciprofloxacin or ofloxacin for < 14 days for treatment of intercurrent infection.
Patients must have:
- HIV infection.
- Signed informed consent.
- Reasonably good health at time of study entry.
- Perceived life expectancy of at least six months.
- Allowed:
- Participation in other clinical trials as long as there is no potential activity of other study drugs against Mycobacterium tuberculosis (MTb), additive toxicities between study agents, or known possible drug interactions between study drugs.
Prior Medication:
Allowed:
- Treatment with quinolones, fluoroquinolones, aminoglycosides, or other agents with known or potential activity against M. tuberculosis.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
- Current active tuberculosis (confirmed or suspected).
- Sensitivity or intolerance to study medication.
- Acute hepatitis.
- Evidence of peripheral neuropathy, i.e., signs or symptoms of paresis, paresthesias, neuromotor abnormalities, or neurosensory deficits of grade 3 or worse.
- Inability to have concomitant medications changed to avoid serious interaction with study drug.
Concurrent Medication:
Excluded:
-
Quinolones, fluoroquinolones, or aminoglycosides with antituberculous activity (may be used for up to 14 days for treatment of intercurrent infection).Other agents with known or potential antituberculous activity should be avoided, including the following:
- Aminosalicylic acid salts, capreomycin, clofazimine, cycloserine, ethambutol, ethionamide, isoniazid, kanamycin, pyrazinamide, rifabutin, rifampin, streptomycin, and thiacetazone.
Prior Medication:
Excluded:
- History of treatment for > 2 months with agents that have known or potential antituberculous activity other than those specifically allowed.
Agents with potential or known antituberculous activity include the following:
- Aminoglycosides such as amikacin, aminosalicylic acid salts, capreomycin, ciprofloxacin, clofazimine, cycloserine, ethambutol, ethionamide, isoniazid, kanamycin, ofloxacin, pyrazinamide, quinolones or fluoroquinolones, rifabutin, rifampin, streptomycin, and thiacetazone.
Patients may not have:
- Current active tuberculosis.
- Acute hepatitis.
- Peripheral neuropathy of grade 3 or grade 4.
Willing and able, in the clinician's opinion, to comply with the treatment and clinical management issues.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Interventional Model: Parallel Assignment
Collaborators and Investigators
Investigators
- Study Chair: Gordin F
- Study Chair: Brown LS
Publications and helpful links
General Publications
- Gordin F, Matts J, Miller C, Chaisson R, Garcia M, O'Brien R. Risk factors for developing active tuberculosis (TB) among HIV-infected, PPD-positive (+) patients (pts). Conf Retroviruses Opportunistic Infect. 1999 Jan 31-Feb 4;6th:151 (abstract no 448)
- New TB guidelines for persons with HIV. AIDS Treat News. 1998 Nov 6;(No 306):6.
- Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, Barry MA, O'Brien RJ. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA. 2000 Mar 15;283(11):1445-50. doi: 10.1001/jama.283.11.1445.
Study record dates
Study Major Dates
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Disease Attributes
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Slow Virus Diseases
- HIV Infections
- Infections
- Communicable Diseases
- Tuberculosis
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antimetabolites
- Micronutrients
- Hypolipidemic Agents
- Lipid Regulating Agents
- Anti-Bacterial Agents
- Leprostatic Agents
- Cytochrome P-450 Enzyme Inducers
- Vitamins
- Cytochrome P-450 CYP3A Inducers
- Vitamin B Complex
- Antitubercular Agents
- Antibiotics, Antitubercular
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C8 Inducers
- Cytochrome P-450 CYP2C19 Inducers
- Cytochrome P-450 CYP2C9 Inducers
- Fatty Acid Synthesis Inhibitors
- Rifampin
- Vitamin B 6
- Pyridoxine
- Isoniazid
- Pyrazinamide
Other Study ID Numbers
- CPCRA 004
- 11556 (Registry Identifier: DAIDS ES Registry Number)
- TB/PPD+
- ACTG 177
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV Infections | HIV SeronegativityUnited States, Puerto Rico
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
Clinical Trials on Pyrazinamide
-
Huashan HospitalUnknownMultidrug Resistant TuberculosisChina
-
Global Alliance for TB Drug DevelopmentCompletedPulmonary TuberculosisSouth Africa
-
Global Alliance for TB Drug DevelopmentActive, not recruitingTuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Multidrug-Resistant | Tuberculosis, MDR | Drug-Resistant TuberculosisGeorgia, South Africa
-
Global Alliance for TB Drug DevelopmentCompleted
-
Obafemi Awolowo University Teaching HospitalUniversity Hospital Birmingham NHS Foundation Trust; Cures Within ReachCompletedTuberculosis | Tuberculosis, PulmonaryUnited Kingdom, Nigeria
-
Taipei Medical University WanFang HospitalUnknown
-
Johns Hopkins UniversityUniversidade Federal do Rio de JaneiroTerminated
-
Global Alliance for TB Drug DevelopmentCompleted
-
Tuberculosis Research Centre, IndiaCompletedHIV Infection | Pulmonary TBIndia
-
NovartisCompletedPostmenopausal OsteoporosisDenmark